3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
211
Triple Negative Breast Neoplasms
32
Inflammatory Breast Neoplasms
21
Breast Neoplasms, Male
5
Primary Breast Cancer
3
Neoplasms
3
Carcinoma, Ductal, Breast
3
Pathologic Complete Response
2
HER2-negative Breast Cancer
2
Cardiotoxicity
2
Breast Diseases
2
Women With Primary Breast Cancer
1
Unilateral HER2 Positive Breast Cancer
1
Sarcoma
1
Resectable HER2-positive Breast Cancer
1
Postoperative Complications
1
Patient Acceptance of Health Care
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neutropenia
1
Neoplastic Cells, Circulating
1
Neoplasm Micrometastasis
1
Neoadjuvant Operable Breast Cancer
1
Kenny-Caffey syndrome, Type 1
1
Hormone Receptor Positive HER-2 Negative Breast Cancer
1
Her2-Positive Breast Cancer
1
HR-positive,HER2-negative Breast Cancer
1
HR+/HER2- Breast Cancer
1
HER2-negative Early Breast Cancer
1
HER2 Positive Early Breast Cancer
1
Interventions
Blood Specimen Collection
6
Trastuzumab
2
Liquid Biopsy
2
Cyclophosphamide
2
Carboplatin
2
ribociclib
1
pertuzumab
1
eribulin
1
Zoledronic Acid
1
Watchful Waiting
1
Thiotepa
1
Surgical Procedures, Operative
1
Stem Cell Transplantation
1
Standard of Care
1
Reverse Transcriptase Polymerase Chain Reaction
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
Microfluidics
1
Letrozole
1
Lapatinib
1
Fulvestrant
1
Flow Cytometry
1
Epirubicin
1
Diphosphonates
1
Digoxin
1
Denosumab
1
Biopsy
1
Atorvastatin
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplastic Cells, Circulating
×
Epirubicin
×
Breast
×
Clear all
NCT04771871
2026-05-07
TARMAC
University College Hospital, Ibadan
Phase 2
Recruiting
42 enrolled